arrow
C

Carlo Genova

IRCCS Ospedale Policlinico San Martino
H指数:38
被引数:6,206

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Host-derived immunometabolic biomarkers identify prognostic profiles under immunotherapy in advanced NSCLC: the SARC-LUNG study

宿主衍生的免疫代谢生物标志物可识别免疫治疗下晚期非小细胞肺癌的预后特征:SARC-LUNG研究

2026-09-110
OA
2026-09-080
OAAI
Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study

PD-L1 ≥ 50% 非小细胞肺癌中cemiplimab单药或联合短程化疗的超进展:一项生物标志物指导的多中心国际II期试验—HYPERBOLIC研究

2026-09-010
PRE
Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to KRAS status: An Italian real-world study

根据KRAS状态评估一线化疗联合免疫疗法在晚期非鳞状NSCLC中的疗效:一项意大利真实世界研究

2026-08-010
PRE
EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the “Rebiopsy on Osi” study)

EGFR突变型非小细胞肺癌对一线奥希替尼进展:真实世界中的再活检及二线疗法的影响(“Rebiopsy on Osi”研究)

2026-07-250
OAAI
Efficacy of Alectinib for ALK-positive NSCLC According to Tumor Burden and Body Mass Index: a Pooled Analysis of the Randomized Phase III Trials ALEX and J-ALEX

根据肿瘤负荷和体重指数评估阿来替尼对ALK阳性NSCLC的疗效:ALEX和J-ALEX随机III期试验的合并分析

2026-06-050
OAAI
Response to Letter Re: Real-World Outcomes of Immunotherapy Discontinuation at Two Years in Advanced Non-Small Cell Lung Cancer: final results of the ISTOP study.

回复函:关于晚期非小细胞肺癌免疫疗法停药两年后的真实世界结局:ISTOP研究的最终结果。

2026-05-020
PRE
Pericardial Mesothelioma: Diagnostic and Therapeutic Management, a Population-Based Study in Italy

心包间皮瘤:诊断与治疗管理——一项意大利基于人群的研究

Cancers
IF4.4
2026-03-040
OAAI
Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study

在晚期非小细胞肺癌中免疫疗法停药两年的真实世界结局:I-STOP研究的最终结果

2026-02-190
PRE
Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World Study
2026-02-030
OAAI
Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas database

Braf突变转移性非小细胞肺癌: 来自意大利生物标志物图谱数据库的真实世界数据

2026-01-210
OAAI
Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥50%: real-world data from the italian ATLAS registry
2025-12-240
OA
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity

长期接受帕博利珠单抗单药治疗的患者中,具有晚期非小细胞肺癌、PD-L1表达≥50%且体力状况较差者的长期结局:基于Transformer的AI用于表征预后复杂性

2025-10-160
OAAI
Diagnostic and Therapeutic Management of Mesothelioma of the Tunica Vaginalis Testis: A Population-Based Study in Italy

睾丸鞘膜间皮瘤的诊断与治疗管理:一项意大利基于人群的研究

2025-10-070
OAAI
EFFECTIVENESS OF TARGET THERAPY IN ADULT AND PEDIATRIC RECURRENT HIGH GRADE GLIOMA PATIENTS WITH BRAFV600E MUTATION OR NTRK FUSION: A REAL-LIFE MULTICENTRIC ITALIAN ANALYSIS.

靶向疗法在成人及儿科复发性高级别胶质瘤患者(携带BRAFV600E突变或NTRK融合)中的有效性:一项意大利多中心真实世界分析。

2025-10-010
OAAI
Advanced-stage ALK-positive non–small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

晚期ALK阳性非小细胞肺癌(NSCLC)患者:来自意大利生物标志物ATLAS数据库的真实世界治疗模式与结果

2025-09-240
OAAI
Influence of medical educational background on the diagnostic quality of ChatGPT-4 responses in internal medicine: A pilot study

医学教育背景对ChatGPT-4在内科学领域诊断质量的影响:一项试点研究

2025-09-080
OAAI
Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses

可切除非小细胞肺癌的免疫疗法:新辅助/围手术期治疗继之以手术优于手术继之以辅助治疗。系统评价与Meta分析及亚组分析

2025-09-050
OAAI
Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study☆

度伐鲁单抗在不可切除的III期非小细胞肺癌且不符合化疗指征的患者放疗后的应用:DUART II期非随机对照研究☆

2025-08-200
PREAI